Arkuda Therapeutics is a pharmaceutical company.
Arkuda Therapeutics has raised $64.0M in total funding. The most recent round was Series B. The last funding was announced in February 2022.
Arkuda Therapeutics's investors include Eli Lilly, Michael J. Fox Foundation, Cormorant Asset Management, Pfizer Venture Investments, Atlas Venture.
Arkuda Therapeutics is headquartered in Cambridge, United States.
Arkuda Therapeutics is a pharmaceutical company.
Arkuda Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Arkuda Therapeutics — Funding & Investors." VCBacked, February 10, 2022, https://www.vcbacked.co/company/arkuda-therapeutics. Accessed July 19, 2026.
VCBacked. (2022). Arkuda Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/arkuda-therapeutics
{{cite web |title=Arkuda Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/arkuda-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated